Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
January 13, 2014 at 07:15 AM EST
Eli Lilly and Company (NYSE: LLY ) today announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of frequent, recurrent migraine headaches. CGRP is a sensory neuropeptide
